Abstract: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.

Abstract: Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for preventing HCMV infections.

Abstract: Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for preventing HCMV infections.

Abstract: A live, attenuated HSV-2 virus and methods of making and using the virus are provided. The live, attenuated HSV-2 virus is constructed using recombinant techniques and can be used in a pharmaceutical composition for prophylactic treatment of HSV-2 infections and for treatment of recurrent HSV-2 related diseases and conditions. Additionally, a plasmid vector is disclosed for expressing a GST-UL56 fusion protein wherein the protein comprises the Glutathione S Transferase gene product fused to at least an immunogenic portion of the HSV-2 UL56 gene product. The GST-UL56 fusion protein can be used to produce polyclonal antisera to the HSV-2 UL56 gene product, to detect whether recombinant HSV-2 deletion mutants express UL56, and as a type-specific reagent capable of discerning HSV-1 from HSV-2.

Abstract: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.

Abstract: Complexes between truncated human cytomegalovirus glycoprotein H (CMV gH) polypeptides and escort proteins are disclosed. The escort proteins include soluble fibroblast growth factor receptor polypeptide and a UL115 polypeptide. The escorts shuttle the CMV gH polypeptides to the cell surface. In this way, egress of the polypeptides out of the cell is facilitated, resulting in increased yields and easier purification of the truncated CMV gH.

Abstract: Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for preventing HCMV infections.

Abstract: Methods for the recombinant expression and secretion of viral proteins are disclosed. The methods involve the use of compatible escorts to shuttle the proteins to the cell surface. In this way, egress of recombinantly produced proteins out of the cell is facilitated, resulting in increased yields and easier purification of the desired protein.